Use of blood group status iii
AssigneeDupont Nutrition Biosciences Aps
InventorsPirjo WACKLIN, Jaana MATTO, Harri MAKIVUOKKO, Jukka PARTANEN, Janne NIKKILA
Life of this patent
Estimating the term…
Loading patent…
AssigneeDupont Nutrition Biosciences Aps
InventorsPirjo WACKLIN, Jaana MATTO, Harri MAKIVUOKKO, Jukka PARTANEN, Janne NIKKILA
Estimating the term…
The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
1-23. (canceled)
A non-secretor/secretor genotype based microbial composition, wherein the composition is tailored based on the spectrum of bacteria found in the mucosal tissue of at least one individual with non-secretor or secretor blood group phenotype.
A method of tailoring a microbial composition based on the spectrum of bacteria found in the mucosal tissue of at least one individual with non-secretor or secretor blood group phenotype.
A method of assessing the need of an individual for optimized microbial supplementation or predicting the microbial composition of the gut microbiota of the said individual by determining the secretor/non secretor blood group status of the individual.
A method for determining the balance of gut microbiota of an individual, the method comprising the steps of:
A method of estimating a dose of microbial supplementation needed for a desired effect in an individual, or augmenting stabilisation of mucosal microbiota of an individual in disorders related to, or after treatments leading to unbalance of mucosal microbiota by determining the secretor/non secretor blood group status of the individual.
Dependencies are inferred from the claim text.